In vitro activation and differentiation of naïve CD4+ and CD8+ T cells into HCV Core- and NS3-specific armed effector cells: A new role for CD4+ T cells

Cellular Immunology

Volumn 259, Issue 2, 2009, Pages 141-149

  Krishnadas, Deepa K ^a   Li, Wen ^a   Kumar, Rakesh ^a   Tyrrell, Lorne J ^a   Agrawal, Babita ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Dendritic cells; Granzyme B; Hepatitis C virus; Immune response; Phenotype

Indexed keywords

CORE PROTEIN; GAMMA INTERFERON; GRANZYME B; NONSTRUCTURAL PROTEIN 3; TOLL LIKE RECEPTOR;

ADENOVIRUS; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HEPATITIS C VIRUS; HUMAN; IMMUNITY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRANZYMES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIGENS; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 70349157236     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.06.009     Document Type: Article

References (53)

1. Berenguer M. Management of hepatitis C virus in the transplant patient. Clin. Liver Dis. 11 (2007) 355-376
2. Pearlman B.L. Hepatitis C treatment update. Am. J. Med. 117 (2004) 344-352
3. + T cells: why the where, when, what and how are important for virus control and infection outcome. Clin. Immunol. 124 (2007) 5-12
4. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
5. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., Rumi M.G., Houghton M., Fiaccadori F., and Ferrari C. Different clinical behaviors of acute hepatitis C infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98 (1996) 706-714
6. + T cells with viral clearance in acute hepatitis C. J. Infect. Dis. 181 (2000) 1528-1536
7. Cucchiarini M., Kammer A.R., Grabscheid B., Diepolder H.M., Gerlach T.J., Grüner N., Santantonio T., Reichen J., Pape G.R., and Cerny A. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell. Immunol. 203 (2000) 111-123
8. + T cell responses during longitudinal study of acute human hepatitis C. Hepatology 42 (2005) 104-112
9. Urbani S., Amadei B., Fisicaro P., Pilli M., Missale G., Bertoletti A., and Ferrari C. Heterologous T cell immunity in severe hepatitis C virus infection. J. Exp. Med. 201 (2005) 675-680
10. + T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms. Eur. J. Immunol. 34 (2004) 427-437
11. Ulsenheimer A., Gerlach J.T., Gruener N.H., Jung M.C., Schirren C.A., Schraut W., Zachoval R., Pape G.R., and Diepolder H.M. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 37 (2003) 1189-1198
12. + T lymphocytes after infection with hepatitis C virus. J. Virol. 75 (2001) 5550-5558
13. Shoukry N.H., Cawthon A.G., and Walker C.M. Cell mediated immunity and the outcome of hepatitis C virus infection. Annu. Rev. Microbiol. 58 (2004) 391-424
14. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., Murthy K.K., Rice C.M., and Walker C.M. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 (2003) 659-662
15. + T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197 (2003) 1645-1655
16. Urbani S., Amadei B., Fisicaro P., Tola D., Orlandini A., Sacchelli L., Mori C., Missale G., and Ferrari C. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 44 (2006) 126-139
17. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 (2005) 946-952
18. + T cell response in acute hepatitis C. Gastroenterology 117 (1999) 933-941
19. Rispeter K., Lu M., Behrens S.E., Fumiko C., Yoshida T., and Roggendorf M. Hepatitis C virus variability: sequence analysis of an isolate after 10 years of chronic infection. Virus Genes 21 (2000) 179-188
20. Li W., Krishnadas D.K., Li J., Tyrrell D.L., and Agrawal B. Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy. J. Immunol. 176 (2006) 6065-6075
21. Li W., Li J., Tyrrell D.L., and Agrawal B. Expression of hepatitis C virus-derived core or NS3 antigens in human dendritic cells leads to induction of pro-inflammatory cytokines and normal T-cell stimulation capabilities. J. Gen. Virol. 87 (2006) 61-72
22. Stordeur P., Poulin L.F., Craciun L., Zhou L., Schandené L., de Lavareille A., Goriely S., and Goldman M. Cytokine mRNA quantification by real-time PCR. J. Immunol. Methods 259 (2002) 55-64
23. + T-lymphocyte subsets using quantitative real-time PCR. Scand. J. Immunol. 58 (2003) 601-606
24. + T cell memory during persistent Trypanosoma cruzi infection. J. Immunol. 181 (2008) 2644-2650
25. Kondrack R.M., Harbertson J., Tan J.T., McBreen M.E., Surh C.D., and Bradley L.M. Interleukin 7 regulates the survival and generation of memory CD4 cells. J. Exp. Med. 198 (2003) 1797-1806
26. - granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J. Immunol. 173 (2004) 1834-1841
27. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M.C., Eichenlaub D., and Pape G.R. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346 (1995) 1006-1007
28. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Robbins G., Phillips R., Klenerman P., and Walker B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191 (2000) 1499-1512
29. Neumann-Haefelin C., Blum H.E., Chisari F.V., and Thimme R. T cell response in hepatitis C virus infection. J. Clin. Virol. 32 (2005) 75-85
30. Guerder S., and Matzinger P. Activation versus tolerance: a decision made by T helper cells. Cold Spring Harb. Symp. Quant. Biol. 54 Pt. 2 (1989) 799-805
31. Keene J.A., and Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155 (1982) 768-782
32. + T cell help. J. Exp. Med. 186 (1997) 65-70
33. Ossendorp F., Mengedé E., Camps M., Filius R., and Melief C.J. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187 (1998) 693-702
34. + T cell responses in vivo. J. Immunol. 171 (2003) 6339-6343
35. + T cell: when, where and how. Annu. Rev. Immunol. 24 (2006) 519-540
36. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., Govindarajan S., Purcell R.H., and Chisari F.V. Viral and immunological determinants of hepatitis C virus clearance, persistence and disease. PNAS 99 (2002) 15661-15668
37. Frese M., Schwarzle V., Barth K., Krieger N., Lohmann V., Mihm S., Haller O., and Bartenschlager R. Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35 (2002) 694-703
38. Yasukawa M., Ohminami H., Arai J., Kasahara Y., Ishida Y., and Fujita S. Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans. Blood 95 (2000) 2352-2355
39. Shresta S., Pham C.T., Thomas D.A., Graubert T.A., and Ley T.J. How do cytotoxic lymphocytes kill their targets?. Curr. Opin. Immunol. 5 (1998) 581-587
40. + T cells in murine skin and heart allograft rejection across different antigenic desparities. Transpl. Immunol. 13 (2004) 297-307
41. Sun Q., Burton R.L., Pollok K.E., Emanuel D.J., and Lucas K.G. CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood. Cell. Immunol. 195 (1999) 81-88
42. + CTL directed against herpes simplex virus-infected cells. J. Immunol. 162 (1999) 6100-6106
43. Gale Jr. M., and Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 436 (2005) 939-945
44. Franco A., Barnaba V., Natali P., Balsano C., Musca A., and Balsano F. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology 8 (1988) 449-454
45. Herkel J., Jagemann B., Wiegard C., Lazaro J.F., Lueth S., Kanzler S., Blessing M., Schmitt E., and Lohse A.W. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocytes. Hepatology 37 (2003) 1079-1085
46. + T cells in chronic hepatitis C virus infection. J. Immunol. 169 (2002) 3447-3458
47. Zabaleta A., Llopiz D., Arribillaga L., Silva L., Riezu-Boj J.I., Lasarte J.J., Borras-Cuesta F., Prieto J., and Sarobe P. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. Mol. Ther. 16 (2008) 210-217
48. Large M.K., Kittlesen D.J., and Hahn Y.S. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J. Immunol. 162 (1999) 931-938
49. Missale G., Cariani E., and Ferrari C. Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies?. Dig. Liver Dis. 36 (2004) 703-711
50. 51Cr-release assay for monitoring cell-mediated cytotoxicity. J. Transl. Med. 1 (2003) 14-22
51. Harari A., Dutoit V., Cellerai C., Bart P.A., Du Pasquier R.A., and Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211 (2006) 236-254
52. Mahajan S.D., Aalinkeel R., Schwatz S.A., Chawda R.P., and Nair M.P. Effector cell mediated cytotoxicity measured by intracellular Granzyme B release in HIV infected subjects. Biol. Proced. Online 5 (2003) 182-188
53. Nigel J.W., Karin A.S., and Chris J.P.C. Granzyme B; the chalk-mark of a cytotoxic lymphocyte. J. Transl. Med. 2 (2004) 36-38